U.S. Biotech Stock News

Multiple law firms have launched securities class action lawsuits against Bitdeer Technologies Group (BTDR), focusing on alleged misstatements around its SEALMINER A4 rigs and SEAL04 chip, following earnings misses and operational setbacks. See our latest analysis for Bitdeer Technologies Group. At a share price of $11.50, Bitdeer’s recent 7 day share price return of 2.59% contrasts with a 90 day share price return decline of 43.93%. Meanwhile, the 1 year total shareholder return decline of...

Wondering if Flagstar Bank National Association at US$12.55 offers good value today, or if the recent run has already priced in the key positives? The stock has been fairly flat year to date at 0.0%, but that sits alongside a 38.1% return over the last year and longer term moves of a 51.1% decline over three years and a 52.9% decline over five years. Recent coverage has focused on Flagstar's position as a regional banking name and how investors are reassessing risk across the sector. This...

Wondering whether Protagonist Therapeutics at around US$82 per share is still offering value, or if the best part of the opportunity has passed? This article is aimed at helping you frame that question clearly. The stock has been volatile in the short term, with a 5.8% decline over the last week and an 8.9% decline over the last month, even though the 1 year return stands at 118.6% and the 5 year return at 285.6%. These sharp moves come against a backdrop of ongoing interest in Protagonist...

W. R. Berkley (WRB) is back on investors’ radar after major shareholder Mitsui Sumitomo bought a large block of shares, lifting its stake materially and drawing attention to the insurer’s valuation and upcoming catalysts. See our latest analysis for W. R. Berkley. The recent insider buying comes after a mixed stretch for W. R. Berkley’s share price. The 30 day share price return of 2.82% has been offset by a 90 day decline of 11.65%, while the 1 year total shareholder return of 21.05%...

If you are wondering whether Fastly's current share price lines up with its underlying worth, or if the market is missing something, this article is for you. Fastly shares last closed at US$10.53, with returns of 3.4% over 7 days, a 5.3% decline over 30 days, 3.3% year to date, 11.8% over 1 year, 13.7% over 3 years and an 88.4% decline over 5 years. Recent coverage of Fastly has focused on how investors are reassessing content delivery and edge computing providers as the sector matures and...

What recent returns say about Palantir Technologies (PLTR) With no single headline event driving Palantir Technologies (PLTR) lately, investors are instead weighing its mixed share performance. This includes a roughly 1% move over the past month and a modest decline over the past 3 months. See our latest analysis for Palantir Technologies. Over the past year, Palantir Technologies has paired an 8.23% year to date share price return with a very large 1 year total shareholder return of 166.28%,...

Hycroft Mining Holding (HYMC) is back on traders’ screens after reporting its highest silver grades to date at the Vortex Silver System in Nevada, alongside a larger ownership stake from billionaire investor Eric Sprott. See our latest analysis for Hycroft Mining Holding. The recent drilling update and Eric Sprott’s higher stake arrive after a sharp shift in sentiment, with a 163.65% 30 day share price return, a 293.91% 90 day share price return, and a very large 1 year total shareholder...

Core & Main (CNM) is back on investor radar after analysts broadly raised their earnings estimates, a shift that often signals changing expectations for how a company’s near term financial results could look. See our latest analysis for Core & Main. At a share price of $53.25, Core & Main has had a mixed year, with recent 30 day and 90 day share price returns of 5.40% and 4.39%, alongside a modest 1 year total shareholder return of 4.04% and a very large 3 year total shareholder return that...

In recent days, analysts have become more optimistic on First Interstate BancSystem, with UBS and others reaffirming Hold views while highlighting improving loan growth, balance sheet trajectory, and disciplined execution ahead of the bank’s late-January 2026 fourth-quarter earnings release and investor call. At the same time, a significant shareholder trimmed their position and the stock’s trading has stayed muted, underscoring how investors are waiting for clearer signals on interest...

In early January 2026, Mobileye announced that a major U.S.-based automaker will use its EyeQ6H chip to power Surround ADAS hands-free driving systems as standard on millions of mainstream and premium vehicles worldwide. The deal lifts Mobileye’s estimated future EyeQ6H Surround ADAS deliveries to more than 19 million units, underlining how software-defined, single-chip architectures are increasingly central to automakers’ next-generation safety and automation plans. We’ll now examine how...

Photronics (PLAB) recently drew investor attention after its shares rose 5.4% in afternoon trading, following more optimistic earnings expectations and supportive news across the semiconductor sector, including stronger revenue guidance from peer Microchip Technology. See our latest analysis for Photronics. Those upbeat earnings expectations sit against a share price of $34.86 and a strong recent run, with a 30-day share price return of 38.06% and a 1-year total shareholder return of 43.93%...

If you are wondering whether Ascendis Pharma's current share price fairly reflects its prospects, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$213.28, with returns of 0.0% over 7 days, 3.0% over 30 days, 0.0% year to date and 58.7% over 1 year, while the 3 year and 5 year returns stand at 87.7% and 28.9% respectively. Recent coverage has focused on Ascendis Pharma's progress and market position in pharmaceuticals and biotech. This...

If you are wondering whether Indivior at around US$35.89 still offers value after a strong run, this article will walk through what the current price might be implying about the company. The stock has delivered a 196.9% return over the last year and a 414.6% return over five years, although the last 30 days saw a 1.9% decline and the last week was flat. Investors have been reacting to ongoing news flow around the company and its position in the pharmaceutical and biotech space, which...

If you are wondering whether KLA's share price still reflects fair value after a strong run, this breakdown will help you see what the current market price might be pricing in. With the stock at US$1,359.69 and reported returns of 11.9% over 7 days, 11.0% over 30 days, 6.7% year to date, 99.8% over 1 year, 234.1% over 3 years and 394.6% over 5 years, many investors are asking what kind of valuation justifies those numbers. Recent coverage has focused on KLA's position in semiconductor...

If you are wondering whether Stanley Black & Decker is offering fair value at around US$78.69, you are not alone. This article is here to break that question into clear, practical pieces. The stock has returned 5.9% over the last 7 days, 8.7% over the last 30 days, 2.9% year to date and 1.0% over the last year, while the 3 year return is 3.2% and the 5 year return reflects a 46.5% decline. Recent coverage has focused on how investors are reassessing long term expectations for tool and...

If you are wondering whether Walt Disney's current share price is a fair deal or not, this article will walk through what the numbers are actually saying about the stock. The shares last closed at US$112.91, with returns of 4.9% over 30 days, 0.9% year to date and 4.0% over 1 year, while the 3 year return is 20.0% and the 5 year return is a 34.4% decline. Recent headlines around Disney have focused on its ongoing efforts to reshape its media and entertainment businesses, including content...

If you are wondering whether Incyte shares still offer value at current levels, you are not alone. This article is designed to walk you through that question step by step. Incyte's share price closed at US$110.57 recently, with total returns of 11.9% over 7 days, 14.3% over 30 days, 9.0% year to date, 51.2% over 1 year, 38.8% over 3 years and 19.2% over 5 years. This naturally raises questions about what is already priced in. Recent news around Incyte has focused on its position in the...

In recent days, Galaxy Digital has seen a jump in trading activity as investors refocused on crypto-related firms amid a recovering Bitcoin market. This renewed attention underscores how closely Galaxy’s diversified digital-asset operations are tied to shifts in broader crypto sentiment and volatility. We’ll now explore how this renewed trading interest, tied to Bitcoin’s recovery, might influence Galaxy Digital’s existing investment narrative. Trump's oil boom is here - pipelines are...

Recent trading in MSC Industrial Direct (MSM) has drawn attention after a one-month return of about a 1% decline and a three-month return of roughly an 8% decline, prompting closer scrutiny of its fundamentals. See our latest analysis for MSC Industrial Direct. Those near term share price declines sit against a softer year to date share price return of 5.6% and a 1 year total shareholder return of 2.3%. This suggests momentum has been fading rather than picking up despite the current US$81.08...

Red Rock Resorts (RRR) has drawn fresh attention after recent share moves, with the stock returning about 9% over the past month and 6.6% in the past 3 months, despite a negative year to date performance. See our latest analysis for Red Rock Resorts. That recent 9% 1 month share price return sits alongside a small year to date share price decline and a much stronger 45.16% 1 year total shareholder return. Together, these figures suggest momentum has cooled in the near term but remains solid...

Altimmune, Inc. recently announced that the FDA has granted Breakthrough Therapy Designation to pemvidutide, its balanced 1:1 glucagon/GLP-1 dual receptor agonist, for treating patients with metabolic dysfunction-associated steatohepatitis (MASH), based on encouraging Phase 2b IMPACT trial data and a completed end-of-phase 2 meeting aligning on a registrational Phase 3 program. The planned Phase 3 trial will not only pursue biopsy-based endpoints for a potential accelerated approval but also...

Full Truck Alliance (NYSE:YMM) is back on investor radar after Hong Kong based Bright Valley Capital built a new US$33.36 million position, and recent revenue data highlights growth in transaction and value added services. See our latest analysis for Full Truck Alliance. Despite Bright Valley Capital’s new stake and solid revenue from transaction and value added services, sentiment around Full Truck Alliance has been mixed, with a 30 day share price return of 8.06% decline and a 90 day share...

Executive share grant and recent pullback put Kinsale in focus Kinsale Capital Group (KNSL) has attracted fresh attention after its share price pullback and a new equity grant of 460 restricted shares to its president and COO, which vests after one year of service. See our latest analysis for Kinsale Capital Group. The recent pullback, including a 16.35% 3 month share price return and a 1 year total shareholder return decline of 5.43%, comes after a strong 3 year total shareholder return of...

Academy Sports and Outdoors (ASO) has recently drawn investor attention after its shares fluctuated between a negative 1-day return and gains over the past week, month, and past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for Academy Sports and Outdoors. The recent 7 day share price return of 13.87% and 30 day gain of 16.46% come after a year to date share price return of 9.09%. At the same time, the 1 year total shareholder return shows a 2.31% decline,...